Skip to main content

Advertisement

SpringerLink
Log in

Gonadal hormone substitutes: Effects on the cardiovascular system

  • Published:
Osteoporosis International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kalin MF, Zumoff B. Sex hormones and coronary disease: a review of the clinical studies. Steroids 1990;55:331–52.

    Google Scholar 

  2. Stampfer MJ, Colditz G. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prevent Med 1991;20:47–63.

    Google Scholar 

  3. Derby CA, Hume AL, Barbour MM, McPhillips JB, Lasater TM, Carleton RA. Correlates of postmenopausal estrogen use and trends through the 1980s in two southeastern New England communities. Am J Epidemiol 1993;137:1125–35.

    Google Scholar 

  4. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756–62.

    Google Scholar 

  5. Criqui MH, Suarez L, Barrett-Connor E, McPhillips J, Wingard DL, Garland C. Postmenopausal estrogen use and mortality: results from a prospective study in a defined, homogeneous community. Am J Epidemiol 1988;128:606–14.

    Google Scholar 

  6. Barrett-Connor E, Wingard DL, Criqui MH. Postmenopausal estrogen use and heart disease risk factors in the 1980s: Rancho Bernardo, Calif., revisited. JAMA 1989;261:2095–100.

    Google Scholar 

  7. Rosenberg L, Shapiro S, Kaufman DW, Slone D, Miettinen OS, Stolley PD. Patterns and determinants of conjugated estrogen use. Am J Epidemiol 1979;109:676–86.

    Google Scholar 

  8. Ravnikar VA. Compliance with hormone therapy. Am J Obstet Gynecol 1987;156:1332–4.

    Google Scholar 

  9. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary artery atherosclerosis by 17β-estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Arteriosclerosis 1990;10:1051–7

    Google Scholar 

  10. Clarkson TB. Estrogens, progestins and coronary heart disease in cynomolgus monkeys. Fertil Steril 1994;62 (Suppl 2):S147–51.

    Google Scholar 

  11. Lobo RA. Hormones, hormone replacement therapy, and heart disease. In: Douglas PS, editor. Cardiovascular health and disease in women. Philadelphia: WB Saunders, 1993:153–73

    Google Scholar 

  12. Wagner JD, Clarkson TB, St. Clair RW, Schwenke DC, Shively CA, Adams MR. Estrogen and progesterone replacement therapy reduces LDL accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J Clin Invest 1991;88:1995–2002.

    Google Scholar 

  13. Wagner JD, Adams MR, Schwenke DC, Clarkson TB. Oral contraceptive treatment decreases arterial LDL degradation in female cynomolgus monkeys. Circ Res 1993;72:1300–8.

    Google Scholar 

  14. Pittman RC, Carew TE, Glass CK, Green SR, Taylor CA Jr., Attie AD. A radioiodinated, intracellularly trapped ligand for determining the sites of plasma protein degradation in vivo. Biochem J 1983;212:791–800.

    Google Scholar 

  15. Wagner JD, St. Clair RW, Schwenke DC, Shively CA, Adams MR, Clarkson TB. Regional differences in arterial low density lipoprotein metabolism in surgically postmenopausal cynomolgus monkeys: effects of estrogen and progesterone therapy. Arterioscler Thromb 1992;12:717–26.

    Google Scholar 

  16. Maseri A, Severi S, De Nes M, et al. “Variant” angina: one aspect of a continuous spectrum of vasospastic myocardial ischemiapathogenic mechanisms, estimated incidence and clinical and coronary arteriographic findings in 138 patients. Am J Cardiol 1978;42:1019–35.

    Google Scholar 

  17. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasocon-striction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046–51.

    Google Scholar 

  18. Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 1990;81:1680–7.

    Google Scholar 

  19. Williams JK, Adams MR, Herrington DM, Clarkson TB. Effects of short-term estrogen treatment on vascular responses of coronary arteries. J Am Coll Cardiol 1992;20:452–7.

    Google Scholar 

  20. Herrington DM, Braden GA, Williams JK, Morgan TM. Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am J Cardiol 1994;73:951–2.

    Google Scholar 

  21. Rosano GMC, Sarrel PM, Poole-Wilson PA, Collins P. Oestrogen improves exercise-induced myocardial ischaemia in female patients with coronary artery disease. Lancet 1993;342:133–6.

    Google Scholar 

  22. Oddens BJ, Boulet MJ, Lehert P, Visser AP. Has the climacteric been medicalized? A study on the use of medication for climacteric complaints in four countries. Maturitas 1992;15:171–81.

    Google Scholar 

  23. Oddens BJ, Boulet MJ, Lehert P, Visser AP. A study on the use of medication for climacteric complaints in western Europe: II. Maturitas 1994;19:1–12.

    Google Scholar 

  24. Ravnikar VA. Compliance with hormone replacement therapy: are women receiving the full impact of hormone replacement therapy's preventive health benefits? Women's Health Issues 1992;2:75–82.

    Google Scholar 

  25. Sismondi P, Biglia N, Giai M, Sgro L, Campagnoli C. Metabolic effects of tamoxifen in postmenopause. Anticancer Res 1994;14:2237–44.

    Google Scholar 

  26. Rossner S, Wallgren A. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 1984;52:339–46.

    Google Scholar 

  27. Bagdade JD, Wolter J, Subbaiah PV, Ryan W. Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. J Clin Endocrinol Metab 1990;70:1132–5.

    Google Scholar 

  28. Bruning P, Bonfrer JM, Hart AA, et al. Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer 1988;58:497–9.

    Google Scholar 

  29. Bertelli G, Pronzato R, Amoroso D, et al. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and anti-thrombin III levels. Breast Cancer Res Treat 1988;12:307–10.

    Google Scholar 

  30. Ingram D. Tamoxifen use, oestrogen binding and serum lipids in postmenopausal women with breast cancer. Aust NZ J Surg 1990;60:673–5.

    Google Scholar 

  31. Love R, Newcombe P, Wiebe DA, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 1990;82:1310–1.

    Google Scholar 

  32. Dewar JA, Horobin JM, Preece PE. Long-term effects of tamoxifen on blood lipid values on breast cancer. Br J Med 1992;305:225–6.

    Google Scholar 

  33. Prentice RL. Tamoxifen as a potential preventive agent in healthy postmenopausal women. J Natl Cancer Inst 1990;82:1310–1.

    Google Scholar 

  34. Shewmon DA, Stock JL, Rosen CJ, et al. Tamoxifen and estrogen lower circulating lipoprotein (a) concentrations in healthy postmenopausal women. Arterioscler Thromb 1994;14:1586–93.

    Google Scholar 

  35. Seed M, Hoppichler F, Reaveley D. Relation of serum lipoprotein (a) concentration and apolipoprotein (a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990;322:1494–9.

    Google Scholar 

  36. Hearn JA, Donohue BC, Ba'albaki H. Usefulness of serum lipoprotein (a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1992;69:736–9.

    Google Scholar 

  37. Hoff HF, Becj GJ, Skibinski CI, Jürgens G. Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. Circulation 1988;77:1238–44.

    Google Scholar 

  38. Murai A, Miyahara T, Fujimoto N, Matsuda M, Kameyama M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 1986;59:199–204.

    Google Scholar 

  39. Williams JK, Wagner JD, Li Z, Golden DL, Adams MR. Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys. Arterioscler Thromb Vasc Biol, 1997 (in press).

  40. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 1991;303:435–7.

    Google Scholar 

  41. Rutqvist LE, Mattsson A, for the Stockholm Breast Cancer Study Group. Cardiac and thromboembolic morbidity among post-menopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 1993;85:1398–406.

    Google Scholar 

  42. Williams JK, Adams MR. The estrogen receptor agonist/ antagonist tamoxifen inhibits progression of coronary artery atherosclerosis in monkeys [abstract]. Circulation 1995;92(Suppl I):I-627

    Google Scholar 

  43. Ke HZ, Simmons HA, Pirie CM, Crawford DT, Thompson DD. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology 1995;136:2435–41.

    Google Scholar 

  44. Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY139481 HC1) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994;93:63–9.

    Google Scholar 

  45. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HC1: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996;11:835–42.

    Google Scholar 

  46. Saarto T, Blomqvist C, Ehnholm C, Taskinen M-R, Elomaa I. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 1996;14:429–33.

    Google Scholar 

  47. Washburn SA, Adams MR, Clarkson TB, Adelman SJ. A conjugated equine estrogen with differential effects on uterine weight and plasma cholesterol in the rat. Am J Obstet Gynecol 1993;169:251–6.

    Google Scholar 

  48. Washburn SA, Honoré EK, Cline JM, Helman M, Wagner JD, Adelman SJ, Clarkson TB. Effects of 17α-dihydroequilenin sulfate on atherosclerotic male and female rhesus monkeys. Am J Obstet Gynecol 1996;175:341–51.

    Google Scholar 

  49. Meeker DR, Kesten HD. Effect of high protein diets on experimental atherosclerosis of rabbits. Arch Pathol 1941;31:147–62.

    Google Scholar 

  50. Balogun EA, Balogun OO, Odutuga AA. Arginine: lysine ratio as a contributory factor to the hypocholesterolemic effect of plant protein sources. IRCS J Med Sci 1982;10:643–4.

    Google Scholar 

  51. Huff MW, Carroll KK. Effects of dietary protein and amino acid mixtures on plasma cholesterol levels in rabbits. J Nutr 1980;110:1676–85.

    Google Scholar 

  52. Huff MW, Hamilton RMG, Carroll KK. Plasma cholesterol levels in rabbits fed low fat, cholesterol-free, semi-purified diets: effects of dietary proteins, protein hydrolysates and amino acid mixtures. Atherosclerosis 1977;28:187–95.

    Google Scholar 

  53. Krichevsky D. Vegetable protein and atherosclerosis. J Am Oil Chem Soc 1979;56:130–40.

    Google Scholar 

  54. Kritchevsky D, Tepper SA, Czarnecki S, Klurfeld DM. Atherogenicity of animal and vegetable protein: influence of the lysine to arginine ratio. Atherosclerosis 1982;47:429–31.

    Google Scholar 

  55. Nagata Y, Ishiwaki N, Sugano M. Studies on the mechanism of antihypercholesterolemic action of soy protein and soy protein-type amino acid mixtures in relation to the casein counterparts in rats. J Nutr 1982;112:1614–25.

    Google Scholar 

  56. Anthony MS, Clarkson TB, Hughes CL Jr., Morgan TM, Burke GL. Soybean isoflavones improve cardiovascular risk factors without affecting the reproductive system of peripubertal rhesus monkeys. J Nutr 1996;126:43–50.

    Google Scholar 

  57. Adlercreutz H. Western diet and Western diseases: some hormonal and biochemical mechanisms and associations. Scand J Lab Clin Invest 1990;50(Suppl 201):3–23.

    Google Scholar 

  58. Clarkson TB, Anthony MS, Hughes CL Jr. Estrogenic soybean isoflavones and chronic disease: risks and benefits. Trends Endocrinol Metab 1995;6:11–6.

    Google Scholar 

  59. Coward L, Barnes NC, Setchell KDR, Barnes S. Genistein, daidzein, and their β-glycoside conjugates: antitumor isoflavones in soybean foods from American and Asian diets. J Agr Food Chem 1993;41:1961–7.

    Google Scholar 

  60. Adlercreutz H, Hämäläinen E, Gorbach S, Goldin B. Dietary phyto-oestrogens and the menopause in Japan [letter]. Lancet 1992;339:1233.

    Google Scholar 

  61. Barnes S, Peterson G, Grubbs C, Setchell K. Potential role of dietary isoflavones in the prevention of cancer. In: Jacobs MM, editor. Diet and cancer: markers, prevention, and treatment. New York: Plenum Press, 1994:135–47.

    Google Scholar 

  62. Knight DC, Eden JA. Phytoestrogens: a short review. Maturitas 1995 ;22:167–75.

    Google Scholar 

  63. Baird DD, Umbach DM, Lansdell L, et al. Dietary intervention study to assess estrogenicity of dietary soy among postmenopausal women. J Clin Endocrinol Metab 1995 ;80:1685–90.

    Google Scholar 

  64. Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 1996;174:93–100.

    Google Scholar 

  65. Bennets HW, Underwood EJ, Shier FL. A specific breeding problem of sheep on subterranean clover pasture in Western Australia. Austr Vet J 1946;22:2–12.

    Google Scholar 

  66. Bradbury RB, White DE. The chemistry of subterranean clover. I. Isolation of formononetin and genistein. J Chem Soc 1951;30:3447–9.

    Google Scholar 

  67. Cheng E, Story CD, Yoder L, Hale WH, Burroughs W. Estrogenic activity of isoflavone derivatives extracted and prepared from soybean oil meal. Science 1953;118:164–5.

    Google Scholar 

  68. Bickoff EM, Livingston AL, Hendrickson AP, Booth AN. Relative potencies of several estrogen-like compounds found in forages. J Agr Food Chem 1993;41:1961–7.

    Google Scholar 

  69. Setchell KDR, Gosselin SJ, Welsh MB, et al. Dietary estrogens: a probable cause of infertility and liver disease in captive cheetahs. Gastroenterology 1987;93:225–33.

    Google Scholar 

  70. Wei H, Wei L, Frenkel K, Bowen R, Barnes S. Inhibition of tumor promotor induced hydrogen peroxide formation in vitro and in vivo by genistein. Nutr Cancer 1993;20:1–12.

    Google Scholar 

  71. Fujio Y, Yamada F, Takahashi K, Shibata N. Responses of smooth muscle cells to platelet-derived growth factor are inhibited by herbimycin — a tryrosine kinase inhibitor. Biochem Biophys Res Commun 1993;195:79–83.

    Google Scholar 

  72. Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J, editors. Cancer incidence in five continents, vol. VI. IARC scientific publication no. 120. Lyon: International Agency for Research on Cancer, 1992.

    Google Scholar 

  73. Cline JM, Foth D. Effects of mammalian and plant estrogens, tamoxifen, and medroxyprogesterone acetate on epithelial proliferation to the mammary glands and uteri of macaques [abstract]. Proc AACR 1996;37:284.

    Google Scholar 

  74. Williams JK, Honoré EK, Washburn SA, Clarkson TB. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol 1994;24:1757–61.

    Google Scholar 

  75. Honoré EK, Williams JK, Anthony MS, Clarkson TB. Soy isoflavones enhance coronary vascular reactivity in atherosclerotic female macaques. Fertil Steril, 1997;67:148–54.

    Google Scholar 

  76. Anthony MS, Clarkson TB, Bullock BC. Soy protein versus soy phytoestrogens (isoflavones) in the prevention of coronary artery atherosclerosis of cynomolgus monkeys [abstract]. Circulation, 1996;94(Suppl 1):I-265.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Comparative Medicine Clinical Research Center, Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, North Carolina, USA

    T. B. Clarkson D.V.M., J. M. Cline, J. K. Williams & M. S. Anthony

Authors
  1. T. B. Clarkson D.V.M.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. M. Cline
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. K. Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. S. Anthony
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clarkson, T.B., Cline, J.M., Williams, J.K. et al. Gonadal hormone substitutes: Effects on the cardiovascular system. Osteoporosis Int 7 (Suppl 1), 43–51 (1997). https://doi.org/10.1007/BF01674813

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01674813

Keywords

Search

Navigation